Trinity Biotech (NASDAQ:TRIB – Get Free Report) and Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and target prices for Trinity Biotech and Treace Medical Concepts, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Trinity Biotech | 1 | 0 | 0 | 0 | 1.00 |
| Treace Medical Concepts | 2 | 4 | 1 | 0 | 1.86 |
Treace Medical Concepts has a consensus target price of $5.17, indicating a potential upside of 7.48%. Given Treace Medical Concepts’ stronger consensus rating and higher possible upside, analysts plainly believe Treace Medical Concepts is more favorable than Trinity Biotech.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Trinity Biotech | -70.06% | N/A | -32.13% |
| Treace Medical Concepts | -28.99% | -71.37% | -30.49% |
Valuation & Earnings
This table compares Trinity Biotech and Treace Medical Concepts”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Trinity Biotech | $43.78 million | 0.17 | -$37.38 million | ($44.26) | -0.21 |
| Treace Medical Concepts | $212.69 million | 1.47 | -$59.00 million | ($0.93) | -5.17 |
Trinity Biotech has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Trinity Biotech has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
Summary
Treace Medical Concepts beats Trinity Biotech on 11 of the 14 factors compared between the two stocks.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
About Treace Medical Concepts
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
